Document is current
Any future updates will be listed below
-
Authors
Beck, Sarah https://orcid.org/0000-0002-7102-8241
Öftering, Patricia https://orcid.org/0000-0002-0967-0049
Li, Renhao https://orcid.org/0000-0002-5806-5080
Hemmen, Katherina https://orcid.org/0000-0003-1852-6513
Nagy, Magdolna
Wang, Yingchun
Zarpellon, Alessandro
Schuhmann, Michael K.
Stoll, Guido
Ruggeri, Zaverio M. https://orcid.org/0000-0003-0807-1295
Heinze, Katrin G. https://orcid.org/0000-0003-2372-6800
Heemskerk, Johan W. M.
Ruf, Wolfram https://orcid.org/0000-0002-6064-2166
Stegner, David https://orcid.org/0000-0003-1059-9865
Nieswandt, Bernhard https://orcid.org/0000-0003-1454-7413
-
Funding
Funding for this research was provided by:
Rudolf Virchow Centre for Integrative and Translational Bioimaging
Foundation for the National Institutes of Health (HL082808, UM1 HL120877)
Deutsche Forschungsgemeinschaft (INST 93/1022-1, 453989101, 374031971, Ni556/14-1)
European Union (Thrombo-Inflame, EFRE–Europäischer Fonds für regionale Entwicklung, Bavaria) Rudolf Virchow Centre for Integrative and Translational Bioimaging
- License Information
-
More Information
Article History
Received: 23 May 2022
Accepted: 15 February 2023
First Online: 23 March 2023
Competing interests
: S.B., D.S. and B.N. hold a patent on recombinant GPV for treating thrombotic diseases reporting sGPV (lacking a functional transmembrane domain) for use in the treatment or prevention of thrombotic diseases. Data on rhGPV preventing thrombus formation in vivo and reducing infarct volume in a tMCAO model in this study are partly covered by the patent (patent applicant, Julius-Maximilians-Universität Würzburg; inventors, B.N., D.S., S.B.; patent published, title, soluble glycoprotein V for treating thrombotic diseases; WO 2017/109212; US patent no. US 11,028,144 B2).
